Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine how the body absorbs decitabine when taken orally
in patients with Myelodysplastic Syndrome (MDS). Safety will also be assessed for this oral
dose.
Cohorts are dosed sequentially, and escalation may stop before the 5th cohort is dosed.
Each cycle will be approximately 4 weeks in length. Following Cycle 1, patients may receive
an additional 4 follow-up cycles of decitabine. Cycles 2-5 will include a 20 mg/m^2 1-hour
IV infusion of decitabine on Days 1-5 for all cohorts.
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials